What is Alexion Pharmaceuticals'stock price?
Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN." What is Alexion Pharmaceuticals' stock price today? One share of ALXN stock can currently be purchased for approximately $182.50. How much money does Alexion Pharmaceuticals make?
Should you hold Alexion Pharmaceuticals (ALXN) stock?
The consensus among Wall Street research analysts is that investors should "hold" Alexion Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALXN, but not buy additional shares or sell existing shares.
How much is an ALXN stock worth?
One share of ALXN stock can currently be purchased for approximately $182.50. How much money does Alexion Pharmaceuticals make? Alexion Pharmaceuticals has a market capitalization of $40.34 billion and generates $6.07 billion in revenue each year.
What did Alexion Pharmaceuticals announce?
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced positive topline results from a Phase 3 study evaluating the safety and efficacy of ULTOMIRIS ® (ravulizumab-cwvz) in adults with generalized...
See more
Who owns Alexion Pharmaceuticals?
AstraZenecaAlexion Pharmaceuticals / Parent organizationAstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. Wikipedia
Did Zeneca buy Alexion?
AstraZeneca today completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company's entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca.
When did AstraZeneca acquire Alexion?
The $39bn deal, announced in December 2020, is AstraZeneca's largest ever acquisition: allowing it to move further into immunology with an enhanced scientific presence, and giving it Alexion's lead medicine soliris (eculizumab), among four other approved medicines and a pipeline of 11 molecules.
Is Alexion a good company to work for?
Alexion is a great place to work and really focused on the patients needs. The Mission and Culture inspires all levels and areas of the company engaging employees on its continuous growth.
Is Pfizer buying AstraZeneca?
Under the terms of the agreement, Pfizer will make an upfront payment of $550 million to AstraZeneca upon the close of the transaction and a deferred payment of $175 million in January 2019.
How much is Alexion worth?
As of 2020, the company's net worth was $24.71 billion. Alexion Pharmaceutical, Inc. is best known for its development of Soliris, a medicine used to treat rare disorders such as aHUS and PNH.
What did AstraZeneca pay for Alexion?
AstraZeneca is splashing out $39 billion to buy Alexion in a cash-and-stock deal, the British pharma revealed Saturday. The deal is driven by AstraZeneca's desire to build a stronger presence in immunology—and to give its top line an immediate boost.
How much did AstraZeneca buy Alexion for?
$39 billionAstraZeneca's mega $39 billion takeover of Alexion Pharmaceuticals has come to a close, delivering the British pharma a lucrative portfolio of immunology medicines and a towering presence in rare diseases.
Who did AstraZeneca buy?
Alexion PharmaceuticalsSept 29 (Reuters) - AstraZeneca (AZN. L) will take full control of Caelum Biosciences in a deal worth up to $500 million, the drugmaker said on Wednesday, sharpening its focus on rare-disease drugs following its purchase of Alexion Pharmaceuticals.
How many people work at Alexion?
approximately 2,500 employeesAlexion has approximately 2,500 employees around the globe and serves patients in more than 50 countries.
Why do you want to work at Alexion?
Alexion is driven by patients, integrity, empowering people and innovating for solutions. Seeks the same in the ideal employee. Getting noticed by Alexion requires a rare combination of talent and transparency. Alexion is dialed into the employee experience transformation.
Where is Alexion Pharmaceuticals located?
Boston, MassachusettsUnited States of America Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening rare disorders. Alexion's global headquarters is in Boston, Massachusetts and its Center of Excellence is based in New Haven, Connecticut.
How much did AstraZeneca buy Alexion for?
$39 billionAstraZeneca's mega $39 billion takeover of Alexion Pharmaceuticals has come to a close, delivering the British pharma a lucrative portfolio of immunology medicines and a towering presence in rare diseases.
Why did AstraZeneca buy Alexion?
The deal is driven by AstraZeneca's desire to build a stronger presence in immunology—and to give its top line an immediate boost. The deal values Alexion at $175 per share, a 45% premium to the Boston biotech's closing price on Friday.
How did AstraZeneca acquire Alexion?
The acquisition will be undertaken through a US statutory merger in which Alexion shareholders will receive $60 in cash and 2.1243 new AstraZeneca ADSs listed on the Nasdaq exchange for each of their Alexion shares.
What did AstraZeneca pay for Alexion?
AstraZeneca — whose Covid-19 vaccine efforts have stumbled in recent weeks — changed the subject by announcing it would buy Alexion in a bid to boost its presence in the rare-disease immunology market.
Is Alexion Pharmaceuticals stock a Buy, Sell or Hold?
Alexion Pharmaceuticals stock has received a consensus rating of hold. The average rating score is and is based on 7 buy ratings, 8 hold ratings, a...
What was the 52-week low for Alexion Pharmaceuticals stock?
The low in the last 52 weeks of Alexion Pharmaceuticals stock was 175.55. According to the current price, Alexion Pharmaceuticals is 103.96% away f...
What was the 52-week high for Alexion Pharmaceuticals stock?
The high in the last 52 weeks of Alexion Pharmaceuticals stock was 187.45. According to the current price, Alexion Pharmaceuticals is 97.36% away f...
What are analysts forecasts for Alexion Pharmaceuticals stock?
The 15 analysts offering price forecasts for Alexion Pharmaceuticals have a median target of 158.80, with a high estimate of 200.00 and a low estim...
How were Alexion Pharmaceuticals' earnings last quarter?
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) posted its quarterly earnings results on Thursday, April, 29th. The biopharmaceutical company reported...
How often does Alexion Pharmaceuticals pay dividends? What is the dividend yield for Alexion Pharmaceuticals?
Alexion Pharmaceuticals declared a quarterly dividend on Wednesday, October 27th. Investors of record on Monday, November 8th will be given a divid...
Who are Alexion Pharmaceuticals' key executives?
Alexion Pharmaceuticals' management team includes the following people: Dr. Ludwig N. Hantson , CEO & Director (Age 58, Pay $4.25M) Dr. Aradhana...
What is Ludwig Hantson's approval rating as Alexion Pharmaceuticals' CEO?
43 employees have rated Alexion Pharmaceuticals CEO Ludwig Hantson on Glassdoor.com . Ludwig Hantson has an approval rating of 75% among Alexion P...
Who are some of Alexion Pharmaceuticals' key competitors?
Some companies that are related to Alexion Pharmaceuticals include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Rege...
What other stocks do shareholders of Alexion Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Gilead Scien...
What is Alexion Pharmaceuticals' stock symbol?
Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."
Who are Alexion Pharmaceuticals' major shareholders?
Alexion Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Ancora Advisors L...
Which major investors are buying Alexion Pharmaceuticals stock?
ALXN stock was purchased by a variety of institutional investors in the last quarter, including Ancora Advisors LLC. View insider buying and selli...
What is the official website of Alexion Pharmaceuticals?
The official website for Alexion Pharmaceuticals is www.alexion.com.
What is Alexion Pharmaceuticals?
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
How much does Alexion Pharmaceuticals make?
Alexion Pharmaceuticals has a market capitalization of $40.34 billion and generates $6.07 billion in revenue each year. The biopharmaceutical company earns $603.40 million in net income (profit) each year or $11.60 on an earnings per share basis.
Barchart Technical Opinion
The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.
Business Summary
Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes...
